Overview

Audentes Therapeutics is a biotechnology company committed to the development and commercialization of innovative new gene therapy treatments for people with serious rare diseases. We are a focused, experienced and passionate team driven by the goal of improving the lives of patients.

We currently have four products in development, AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM), AT342 for the treatment of Crigler-Najjar Syndrome, AT307 for the treatment of CASQ2-related Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT), and AT982 for the treatment of Pompe disease.
Stock Information
BOLD (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$18.84
Change (%) Stock is Up 1.07 (6.02%)
Volume111,084
Data as of 06/22/17 11:57 a.m. ET
Refresh quote
Stock chart for: BOLD.O.  Currently trading at $18.84 with a 52 week high of $20.74 and a 52 week low of $13.06.
Recent NewsMore >>
06/13/17
Audentes Therapeutics Appoints Jennifer Jarrett to Board of Directors
05/11/17
Audentes Therapeutics Reports First Quarter 2017 Financial Results and Provides Corporate Update
05/10/17
Audentes Therapeutics to Present At Upcoming Investor Conferences
Upcoming EventsMore >>
There are currently no events scheduled.
Primary IR Contact
Thomas Soloway
SVP and Chief Financial Officer
Audentes Therapeutics, Inc.
E-mail: ir@audentestx.com

Data provided by Nasdaq. Minimum 15 minutes delayed.